An Executive Informational Overview (EIO) is now available on NKore Biotherapeutics, LLC, a cellular-based biotherapeutics company focused on the early detection, prevention, and treatment of cancer. The 60-page report details the Company's business, its strategy, market opportunities, competition, risks, and more. It is available for download below.
Snapshot
NKore Biotherapeutics, LLC (“NKore” or “the Company”) is a cellular-based biotherapeutics company focused on the early detection, prevention, and treatment of cancer. The Company’s technology is based on a proprietary method of activating natural killer (NK) cells, creating Supercharged Natural Killer (sNK) cells used as a novel oncology immunotherapy platform. NKore’s proprietary activation method enhances NK cells’ overall effectiveness, making them significantly more potent (i.e., they are more cytotoxic to the cancer cells), while reducing the likelihood of tumor regeneration and metastasis. The technology was developed by Dr. Anahid Jewett, the Company’s co-founder and Chief Scientific Advisor. Based on positive preclinical results, the Company believes that Dr. Jewett’s 30-plus years of researching NK cell function has resulted in the development of a novel and effective cancer immunotherapy. NKore’s current focus is to translate and replicate the positive preclinical results into human clinical trials and achieve marketing approval. To support its immunotherapy initiative, NKore also intends to commercialize a proprietary companion cell-based diagnostic screening platform to monitor the patient’s immune function to measure response to therapy and assist physicians in the development of better personalized treatment plans.
Key Points of NKore Biotherapeutics, LLC
- Working with Dr. Jewett, NKore has developed NK101, a non-engineered cellular immunotherapy for the treatment of both solid tumors and hematologic malignancies.
- Preclinical studies have demonstrated NK101’s ability to stop or reverse disease progression as well as to reduce the metastatic potential in preclinical models for many forms of cancer, including glioblastoma, pancreatic, melanoma, oral, lung, and ovarian cancer, as well as hematologic malignancies.
- NKore has initiated human clinical use outside the U.S. using NK101 as a palliative treatment option for patients with metastatic or unresectable cancers. Initial clinical use in Cancun, Mexico, includes two patients to demonstrate the safety of NK101. With additional clinical data, the Company intends to file an Investigational New Drug (IND) application with the FDA seeking approval to commence clinical trials in the U.S.
- NK101’s safety profile appears excellent, with neither patient experiencing any adverse side effects or discomfort after therapy.
- At 60 days post-infusion, Patient 1 (a 64-year-old male diagnosed with a form of non-Hodgkin’s lymphoma and presenting with a genetic mutation that limits his ability to respond to conventional therapy) saw a 75% reduction in tumor cell infiltration in the bone marrow, as well as a significant reduction in the size of enlarged lymph nodes.
- Early results in Patient 2, an 11-year-old girl diagnosed with an incurable Optic Pathway Glioma brain tumor, demonstrate NK101’s positive safety profile even in a pediatric patient.
- Since formation, NKore has completed funding activities totaling approximately $3.2 million.
*******************************************
Visit our Corporate Profile and Investment Highlights pages
for the latest research on NKore Biotherapeutics, LLC
*******************************************